---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-262576"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:55.975430+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M

## Summary
- Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.
- Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).
- 204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.
- Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.
- First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study.

## SEC filing metadata
- accession: 0001193125-25-262576
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/0001193125-25-262576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/d21938d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-262576
- JSON: https://secwatch.observer/filing/0001193125-25-262576.json
- Plain text: https://secwatch.observer/filing/0001193125-25-262576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.